# Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

> **NCT02014636** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02014636
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-27
- **Primary completion:** 2019-02-27
- **Final completion:** 2019-02-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014636, "Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02014636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*